Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia


Cite item

Full Text

Abstract

The review considers trials dealing with the efficiency of combination hypolipidemic therapy with simvastatin and ezetimibe. Its synergistic potentiating effect can cause a considerable decrease in the level of total cholesterol, low-density lipoproteins, triglycerides, and C-reactive protein, which are important participants in the atherogenic process. This effect promotes the achievement of hypolipidemic therapeutic goals in many cases when this cannot be attained by high-dose statin monotherapy. The authors consider the results of trials of combination hypolipidemic therapy with simvastatin and ezetimibe performed as basic ones done in both previous and recent years

Full Text

Гиполипидемические и плейотропные эффекты комбинации симвастатина и эзетимиба у больных различными видами гиперлипидемий. - Аннотация. В обзоре рассмотрены работы по применению комбинированной гиполипидемической терапии симвастатином и эзетимибом. Синергичный потенцирующий эффект позволяет вызвать значительное снижение уровня общего холестерина, липопротеидов низкой плотности, триглицеридов, а также С-реактивного белка - важных участников процесса атерогенеза. Этот эффект способствует достижению целевого уровня гиполипидемической терапии во многих случаях, когда его не удается достичь с помощью монотерапии высокими дозами статинов. Рассмотрены результаты работ как основных, так и проведенных в последние годы, касающиеся комбинированной гиполипидемической терапии симвастатином и эзетимибом.
×

About the authors

A B Sumarokov

V V Kukharchuk

Email: v_kukharch@mail.ru

References

  1. Cholesterol Treatment Trialist (CTT) Collaboration, Efficacy and Safety of More Intencive Lowering of LDL cholesterol: a meta analysis of data from 1700 000 participants in 26 randomized trials. Lancet 2010; 376: 1670-1681.
  2. Altman S.W., Davies H.R., Zhu U. et al. Nieman-Pick Cl-like 1 protein is critical for intestinal absorption. Science 2004; 303: 1201-1204.
  3. Sudhop T., Lutjohann D., Kodal A. et al. Inhibiion of Intestinal Cholesterol Absorbtion by Ezetimibe in Humans. Circulation 2002; 106: 1943-1948.
  4. Tremblay A.J., Lamarche B., Lemelin V. et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J Lipid Research, 2011; 52, 558-565.
  5. Kalogirou M., Tsimihodimos V., Saougos V. et al. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment Arch Med Sci 2007; 3 (4): 344-350.
  6. Habara M., Vasu K., Terashima M. et al. Impact of Optical Coherence Tomographic Findings of Fluvastatin Alone Versus Fluvastatin + Ezetimibe. 2014; 113 (4): 580-587.
  7. Robinson J.G., Ballantyne C.M., Grundy S.M. et al. Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With hypercholesterolemia and the Metabolic Syndrom (from the VYMET Study). Am J Cardiol 2009; 103: 1694-1702.
  8. Yoon H.S., Kim S.H., Kim J.K. et al. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia. Ann Pharmacother 2011; 45 (7): 841-849.
  9. Abramson B.L., Benlian P., Hanson M. et al. Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients. Lipids in Health and Disease 2011; 10: 146.
  10. Toth P.P., Morrone D., Weintraub W.S. et al. Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks. Int J Clin Prat 2012; 66 (8) 800-813.
  11. Peto R., Emberson J., Landray M. et al. Analysis of cancer data from three ezrtimibe trials. N Engl J Med 2008; 39: 1359-1366.
  12. Ben-Yehuda O., Wenger N.K., Constance C. et al. The comparative efficacy of ezetimibe added to atorvastatin 10 мг versus uptitration to atorvastatin 40 mg in subgroops of patients aged 65 to 74 or greater than or equal to 75 years. J Geriatr Cardiol 2011; 8: 1-11.
  13. Constance C., Ben-Yehuda O., Wenger N.K. et al. Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attateiment of European and Canadian guedline lipid targets in high-risk subjects ≥65 years. Lipids in Health and Disease 2014; 13: 13.
  14. Catapano A., Brady W.E., King T.R., Palmisano J. Lipuid-altering efficacy of ezetimibe coadministered with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005; 21 (7): 1123-1130.
  15. Friedman H.S., Rajagopalan S., Barnes J.P. et al. Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Low-Density Lipoprotein Cholesterol Reduction and Goal Attainment in Real-World Clinical Setting. Clin Ther 2011; 33: 212-224.
  16. Farnier M., Guyton J.R., Jensen E., Polis A.B. Effects of ezetimibe/simvastatin on correlations between apolipoproteinB, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. Atherosclerosis 2013; 229 (2): 415-422.
  17. Kastelein J.J.P., Akdim F., Stroes E.S.G. et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. Engl J Med 2008; 358 (14): 1431-1443.
  18. Lipka L., Sager P., Strony J. et al. Ezetimibe Study Group. Efficacy and safety of coadministration and statins in elderly patients with primary hypercholesterolemia. Drugs Aging 2004; 21 (15): 1025-1032.
  19. Pearson Т.А., Denke M.A., McBride P.E. et al. A community-based randomized trial of ezetimib added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimib add-on to statin for effectiveness (EASE) trial. Mayo Clinic Proc 2005; 80 (5): 587-595.
  20. Baigent C., Landray M.J., Reith С. et al. The Effects of Lowering LDL cholesterol with simvastatin plus ezetimib in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial). Lancet 2011; 337: 2181-2192.
  21. Pandey A.S., Bissonette S., Boukas S. et al. Effectiveness and tolerability of ezetimibe co-administrated with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial, Arch Med Sci 2011; (5): 767-775.
  22. Morrone D., Weintraub W.S., Toth P.P. et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012; 223: 251-261.
  23. Foody J.M., Brown W.V., Zieve F. et al. Safety and Efficacy of Ezetimibe/Simvastatin Combination Versus Atorvastatin Alone in Adults >65 Years of Age With Hypercholesterolemia and With or at Moderately High/High Risk for Coronary Heart Disease (the VYTELD Study). Am J Cardiol 2010; 106 (9): 1255-1263.
  24. Ballantyne C.M., Weiss R., Moccetti et al. Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe In Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). Am J Cardiol 2007; 99: 673-680.
  25. Yu Ch-Ch, Lai W.-T., Shih K.-C. et al. Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling statin the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC Research Notes 2012; 5: 251-258.
  26. Abate N., Catapano A.L., Ballantyne C.M. et al. Effects of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on, modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. J Clin Lipidol 2008; 2 (2): 91-105.
  27. Pearson T., Ballyntyne C., Sisk C. et al. Comparison of Effect of Ezetimibe/Simvastatin Versus Simvastatin Versus Atorvastatinin Reducing C-Reactive Protein and Low-Density Lipoprotein Choplesterol Levels. Am J Cardiol 2007; 99: 1706-1713.
  28. Jimenez J.G., Rosen J.B., Pirags V. et al. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabet Obes Metabol 2013; 15 (6): 513-522.
  29. Соколова Н.А., Явелов И.С., Белоусов Ю.Б. и др. Невысокие дозы статинов и комбинация статина с эзетимибом у больных каротидным атеросклерозом: влияние на липиды крови, маркеры воспаления и толщину комплекса интима-медиа. Фарматека 2010; 5: 106-111.
  30. Миклишанская С.В., Власик Т.Н., Хеймец Г.И. и др. Влияние интенсивной гиполипидемической терапии на концентрацию липопротеинассоциированной фосфолипазы А2 в крови больных ишемической болезнью сердца. Кардиология 2013; 9: 4-11.
  31. Moutsouri E., Liberopoulos E., Tellis C. et al. Comparison of the effect of simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis 2013; 231: 8-14.
  32. Maki-Petaja K.M., Booth A.D., Hall F.C. Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endotelial Function in Rheumatoid Arthritis. JACC 2007; 50: 852-858.
  33. Krysiak R., Zmuda W., Okopien B. The Effects of ezetimibe, administrered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 2012; 271: 32-42.
  34. Gouni-Bertold I., Bertold I., Chamberland J.P. et al. Short-term treatment with ezetimibe, simvastatine or their combination does not alter circulating adiponectin, resistin or leptin in healthy men. Clin Endocrinol 2008; 68: 536-541.
  35. Sternberg Z., Chichelli T., Sternberg D. et al. Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. Atherosclerosis 2013; 231: 411-420.
  36. Fleg J., Mete M., Howard B.V. et al. Effects of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes. The SANDS (STOP Atherosclerosis in Native Diabetics Study) Trial. JACC 2008; 52: 2198-2205.
  37. Bardini G., Giorda C.B., Pontiroli A.E. et al. Ezetimibe + simvastatine versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol 2010; 9 (1): 20-28.
  38. Ruggenenti P., Bossi A., Cattaneo D. et al. Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes. A prospective randomized double-blind clinical trial. Diabetes Care 2010; 33 (9): 1954-1956.
  39. Kater A.-L.A., Batista M.C., Ferreira S. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metabol Syndrome 2010; 2 (1): 34-41.
  40. Derosa G., DAngelo A.D., Franzetti I.G. et al. Efficacy and safety of ezetimibe/simvastatinassociation on non- diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standart statin treatment. J Clin Pharm Ther 2009; 34: 267-276.
  41. Rosen J.B., Jimenez J.G., Pirags V. et al. Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. Lipids in Health and Disease 2013; 12 (1): 103-113.
  42. Leiter L.A., Betteridge D.J., Farnier M. et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabet Obes Metabol 2011; 13: 615-628.
  43. Peters S.A.E., Hessler M., den Ruiter. et al. Results From a Carotid Intima-Media Thickness Trial as a Decision Tool for Launching a Large-Scale Morbidity and Mortality Trial. Circulation 2013; 6: 20-25.
  44. Villines T., Stanec E.J., Devine P.J. et al. The Arbiter 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Strategies in Atherosclerosis). JACC 2010; 55: 2721-2726.
  45. Berneis K., Rizzo M., Bertold H.K. et al. Ezetimibe alone or in combination with simvastatin increase small dense low-density lipoprotein in healthy men: a randomized trial. Eur Heart J 2010; 31: 1633-1639.
  46. Taylor A.J., Villines T.C., Stanek E. Paradoxal progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. Eur Heart J 2012; 33: 2939-2345.
  47. Settergren M., Bohm F., Ryden L., Pernow J. Cholesterol lowering is more impotent than pleiotropic effects of statins for endothelial function in patients with dysglycemia ang coronary artery disease. Eur Heart J 2008; 29: 1753-1760.
  48. Araujo D.B., Bertolani M.C., Ferreira W.P. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparison study between simvastatin and simvastatin/ezetimibe coadministration. J Cardiovasc Pharmacol 2010; 55 (1): 1-5.
  49. Ye Y., Zhao X., Zhai G. et al. Effect of High-Dose Statin Versus Low-Dose Statin Plus Ezetimibe on Endotelial Function: A Meta-analysis of Randomized Trials. J Cardiovasc Pharmacol Ther 2012; 17: 357.
  50. Dubic G., Tremblay M., Pare G. et al. A new method of measurement of total, plasma PCSK9 : clinical applications. J Lipid Res 2010; 51: 140-149.
  51. Bertold H.K., Seydah N.G., Benjannet S., Gouni-Bertold I. Evidence from a randomized Trial That Simvastatin, but Not Esetimibe, Upregulates Circulating PCSK9 levels. PLOS ONE 2013; 8 (3): e60095.
  52. Lakoski S.G., Xu F., Vega G. et al. Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin. J Clin Endocrinol Metab 2010; 95: 800-809.
  53. Bays H.E., Averna M., Majul C. et al. Efficacy and ;Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rozuvastatin in Patients With Primary Hypercholesterolemia. Am J Cardiol 2013; 112 (12): 1885-1895.
  54. Zieve F., Wenger N.K., Ben Yehuda O. et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or = 65 years of age (from the ZETIA in the ELDerly (ZETELD ) study. Am J Cardiol 2010; 105: 656-663.
  55. Baigent C., Landray M.J., Reith С. et al. The Effects of Lowering LDL cholesterol with simvastatin plus ezetimib in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial). Lancet 2011; 337: 2181-2192.
  56. Rossebo A.B., Pedersen T.R. Allen С. et al. Desigh and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am J Cardiol 2007; 99: 970-973.
  57. Rossedo A.B., Pedersen T.R., Boman K. et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. Engl J Med 2008; 359: 1343-1356.
  58. Patel A.Y., Pillarisetti J., Vacek J.L. et al. Ezetimibe in Combination With Statin Does Not Reduce All-Cause Mortality. J Clin Med Sci 2013; 5 (4): 275-280.
  59. Hayek S., Escaro F.C., Sattar A. et al. Effects of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality. Am J Cardiol 2013; 111 (4): 532-539.
  60. Ballantyne Ch.M., Abate N., Yuan Zh. et al. Dose-comparison study of the combination of ezetimibe and simvastatin (VYTORIN) versus atorvastatin in patients with hypercholesterolemia: The VYTORIN Versus Atorvastatin (VYVA) Study. Am Heart J 2005; 149: 464-473.
  61. Farmer J. Effect of Ezetimibe on Carotid Intimal Thickness: The VYCTOR Study. Curr Atheroscler Report 2010; 12: 288-290.
  62. Davidson M.H., McGarry T., Bettis R. et al. Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia. JACC 2002; 40: 2125-2134.
  63. Bays H.E., Ose L., Fraser N. et al. A multicenter, randomized , double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004; 11: 1758-1773.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies